{
    "clinical_study": {
        "@rank": "63917", 
        "arm_group": [
            {
                "arm_group_label": "Standard infant formula", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Standard infant formula fed ad libitum"
            }, 
            {
                "arm_group_label": "Standard infant formula with PL1", 
                "arm_group_type": "Experimental", 
                "description": "Standard infant formula enriched with PL1 lipid fraction fed ad libitum"
            }, 
            {
                "arm_group_label": "Standard infant formula with PL2", 
                "arm_group_type": "Experimental", 
                "description": "Standard infant formula enriched with PL2 lipid fraction fed ad libitum"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, randomized, double-blind, parallel-group, reference-controlled\n      4-month pilot safety study to evaluate the effects of specific lipid fractions-enriched\n      infant formulae on growth of infants aged 0-4 months. The study will test the hypothesis\n      that growth of infants fed the specific lipid fractions-enriched infant formulae will be\n      noninferior to growth of infants fed standard infant formula."
        }, 
        "brief_title": "Effects of Specific Lipid Fractions-enriched Infant Formulae", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Infant Growth", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy newborn infant\n\n          -  Infant is \u226414 days old on day of enrollment\n\n          -  Gestational age \u226537 weeks (full term infants)\n\n          -  Birth weight \u22652500 g and \u22644500 g\n\n          -  Singleton birth\n\n          -  Having obtained his/her parents'/legal representative's informed consent\n\n        Exclusion Criteria:\n\n          -  Having any significant pre-natal and/or post-natal disease and/or congenital illness\n             or malformation that may affect normal growth.\n\n          -  Infant undergoing antibiotic therapy.\n\n          -  Re-hospitalization for more than 2 days in the first 14 days of life.\n\n          -  Parents not expected to comply with the protocol during the period of study\n             participation.\n\n          -  Infants currently participating in another trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "14 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "199", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111837", 
            "org_study_id": "07.16.INF.B"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard infant formula", 
                "intervention_name": "Standard infant formula", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Standard infant formula with PL1", 
                "intervention_name": "Standard infant formula with PL1", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Standard infant formula with PL2", 
                "intervention_name": "Standard infant formula with PL2", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "state": "Cedex 9", 
                        "zip": "14033"
                    }, 
                    "name": "CHU de Caen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "state": "Cedex 9", 
                        "zip": "37044"
                    }, 
                    "name": "H\u00f4pital Bretonneau - UPM"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "Groupe Hospitalier Pellegrin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "zip": "90127"
                    }, 
                    "name": "Istituto di Ostetricia e Ginecologia Neonatalogia"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Italy"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Multicenter, Randomized, Double-blind, Parallel-group, Reference-controlled, Safety Pilot Study to Evaluate the Effects of Specific Lipid Fractions-enriched Infant Formulae in Infants Aged 0-4 Months", 
        "overall_official": {
            "affiliation": "H\u00f4pital des enfants, CHU Pellegrin, Bordeaux, France", 
            "last_name": "Claude Billeaud, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "France: Committee for the Protection of Personnes", 
                "Italy: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean weight gain (g/day)", 
            "safety_issue": "Yes", 
            "time_frame": "Enrollment to age 4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111837"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Nestl\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nestl\u00e9", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}